These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 9145874)

  • 1. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity.
    Daluge SM; Good SS; Faletto MB; Miller WH; St Clair MH; Boone LR; Tisdale M; Parry NR; Reardon JE; Dornsife RE; Averett DR; Krenitsky TA
    Antimicrob Agents Chemother; 1997 May; 41(5):1082-93. PubMed ID: 9145874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89.
    Faletto MB; Miller WH; Garvey EP; St Clair MH; Daluge SM; Good SS
    Antimicrob Agents Chemother; 1997 May; 41(5):1099-107. PubMed ID: 9145876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile.
    Daluge SM; Purifoy DJ; Savina PM; St Clair MH; Parry NR; Dev IK; Novak P; Ayers KM; Reardon JE; Roberts GB
    Antimicrob Agents Chemother; 1994 Jul; 38(7):1590-603. PubMed ID: 7526782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89.
    Tisdale M; Alnadaf T; Cousens D
    Antimicrob Agents Chemother; 1997 May; 41(5):1094-8. PubMed ID: 9145875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine.
    Kong XB; Zhu QY; Vidal PM; Watanabe KA; Polsky B; Armstrong D; Ostrander M; Lang SA; Muchmore E; Chou TC
    Antimicrob Agents Chemother; 1992 Apr; 36(4):808-18. PubMed ID: 1503443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol.
    Nair V; St Clair MH; Reardon JE; Krasny HC; Hazen RJ; Paff MT; Boone LR; Tisdale M; Najera I; Dornsife RE
    Antimicrob Agents Chemother; 1995 Sep; 39(9):1993-9. PubMed ID: 8540705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine.
    de Muys JM; Gourdeau H; Nguyen-Ba N; Taylor DL; Ahmed PS; Mansour T; Locas C; Richard N; Wainberg MA; Rando RF
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1835-44. PubMed ID: 10428900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Membrane permeation characteristics of abacavir in human erythrocytes and human T-lymphoblastoid CD4+ CEM cells: comparison with (-)-carbovir.
    Mahony WB; Domin BA; Daluge SM; Zimmerman TP
    Biochem Pharmacol; 2004 Nov; 68(9):1797-805. PubMed ID: 15450945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral activity, biochemistry, and pharmacokinetics of 3'-azido-2',3'-dideoxy-5-methylcytidine.
    Schinazi RF; Chu CK; Eriksson BF; Sommadossi JP; Doshi KJ; Boudinot FD; Oswald B; McClure HM
    Ann N Y Acad Sci; 1990; 616():385-97. PubMed ID: 1706574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants.
    Gu Z; Wainberg MA; Nguyen-Ba N; L'Heureux L; de Muys JM; Bowlin TL; Rando RF
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2376-82. PubMed ID: 10508010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study.
    McDowell JA; Chittick GE; Ravitch JR; Polk RE; Kerkering TM; Stein DS
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2855-61. PubMed ID: 10582871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
    Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
    Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro.
    Drusano GL; D'Argenio DZ; Symonds W; Bilello PA; McDowell J; Sadler B; Bye A; Bilello JA
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2153-9. PubMed ID: 9736527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antiviral activity, mechanism of action, clinical significance and resistance of abacavir in the treatment of pediatric AIDS.
    Melroy J; Nair V
    Curr Pharm Des; 2005; 11(29):3847-52. PubMed ID: 16305515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate.
    Ray AS; Yang Z; Shi J; Hobbs A; Schinazi RF; Chu CK; Anderson KS
    Biochemistry; 2002 Apr; 41(16):5150-62. PubMed ID: 11955063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of the carbocyclic nucleoside analogue carbovir, an inhibitor of human immunodeficiency virus, in human lymphoid cells.
    Bondoc LL; Shannon WM; Secrist JA; Vince R; Fridland A
    Biochemistry; 1990 Oct; 29(42):9839-43. PubMed ID: 2271622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism of carbovir, a potent inhibitor of human immunodeficiency virus type 1, and its effects on cellular metabolism.
    Parker WB; Shaddix SC; Bowdon BJ; Rose LM; Vince R; Shannon WM; Bennett LL
    Antimicrob Agents Chemother; 1993 May; 37(5):1004-9. PubMed ID: 7685993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults.
    Kumar PN; Sweet DE; McDowell JA; Symonds W; Lou Y; Hetherington S; LaFon S
    Antimicrob Agents Chemother; 1999 Mar; 43(3):603-8. PubMed ID: 10049274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity.
    Witvrouw M; Arranz ME; Pannecouque C; Declercq R; Jonckheere H; Schmit JC; Vandamme AM; Diaz JA; Ingate ST; Desmyter J; Esnouf R; Van Meervelt L; Vega S; Balzarini J; De Clercq E
    Antimicrob Agents Chemother; 1998 Mar; 42(3):618-23. PubMed ID: 9517942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.